TABLE 3.
Subgroup analyses of UAER based on treatment duration, baseline of 24h-UTP, baseline of Scr and type of RASI.
| Criteria for grouping | Subgroups | n | MD (95%CI) | I2(%) | Z | P |
|---|---|---|---|---|---|---|
| Treatment duration | 8 weeks | 11 | −33.06 (−44.41, −21.70) | 97 | 5.70 | <0.00001 |
| 12 weeks | 5 | −23.88(−27.25, −20.51) | 0 | 13.89 | <0.00001 | |
| ≥16 weeks | 2 | −8.12(−12.72, −3.52) | 0 | 3.46 | 0.0005 | |
| Baseline of 24h-UTP | <1 g | 2 | −15.48(−18.94, −12.03) | 0 | 3.56 | <0.00001 |
| 1–2 g | 3 | −19.75(−22.52, −16.97) | 0 | 16.58 | <0.00001 | |
| >2 g | 2 | −63.73(−173.96, 46.51) | 100 | 7.35 | 0.26 | |
| Baseline of Scr | <90 μmol/L | 7 | −32.04(−49.77, −14.32) | 98 | 3.54 | 0.0004 |
| 90–110 μmol/L | 7 | −22.24 (−26.74, −17.74) | 65 | 9.68 | <0.00001 | |
| 110–133 μmol/L | 2 | −27.01(−32.79, −21.24) | 0 | 9.17 | <0.00001 | |
| Type of RASI | ACEI | 3 | −50.63(−125.86,24.61) | 99 | 1.32 | 0.19 |
| ARB | 15 | −22.73(−26.35, −19.11) | 81 | 12.31 | <0.00001 |
RASI, Renin-angiotensin-aldosterone system inhibitor; ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin-receptor blocker; 24h-UTP, 24h-urine total protein; Scr, Serum creatinine.